Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

I presume there are provisions in the 40mg-Glatopa fill/finish contract to deal with regulatory compliance issues at PFE's facility, but these provisions could take any number of forms. For instance, they might dictate a method of calculating monetary damages (to apply as a credit against future orders). Alternatively, the contract might say that any unresolved disagreement goes to arbitration.

I wouldn't count on receiving much detail about this on Tuesday's CC, although MNTA might reveal in general terms whether they have any recourse.